Group 1 - The company has approved a share repurchase plan using its own and/or raised funds, with a total repurchase amount between RMB 50 million and RMB 100 million, and a maximum repurchase price of RMB 14 per share, within a 12-month period [2] - Following the implementation of the 2024 annual equity distribution, the maximum repurchase price has been adjusted to RMB 13.90 per share starting from July 17, 2025 [3] - As of July 31, 2025, the company has repurchased a total of 1,999,400 shares, accounting for 0.24% of the total share capital, with a total payment of RMB 15,535,845.00, excluding transaction fees [4] Group 2 - The company's stock experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over three consecutive trading days from July 29 to July 31, 2025 [10][11] - The company confirmed that there are no undisclosed significant matters affecting the stock price, and the production and operation are normal [12][13] - There were no media reports or market rumors identified that could significantly impact the stock price during the abnormal trading period [14]

Core Viewpoint - Zhejiang Aoxiang Pharmaceutical Co., Ltd. has announced the progress of its share repurchase plan, which aims to enhance shareholder value and implement employee stock ownership plans through the repurchase of shares [1][2]. Summary by Sections Share Repurchase Plan Overview - The share repurchase plan was first disclosed on January 27, 2025, with an implementation period from January 24, 2025, to January 23, 2026 [1]. - The expected total repurchase amount is between RMB 50 million and RMB 100 million [1]. - The repurchased shares will be used for employee stock ownership plans and/or equity incentives [1]. Progress of Share Repurchase - As of July 31, 2025, the company has repurchased a total of 1,999,400 shares, representing 0.24% of the total share capital [2]. - The total amount spent on the repurchase is RMB 15,535,845, with a price range of RMB 7.52 to RMB 8.57 per share [2]. Adjustments to Repurchase Terms - Following the annual equity distribution for 2024, the maximum repurchase price was adjusted from RMB 14 per share to RMB 13.90 per share starting July 17, 2025 [2]. Compliance and Future Actions - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations regarding the progress of the share repurchase [3].

证券代码：603229 证券简称：奥翔药业 公告编号：2025-034 浙江奥翔药业股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 浙江奥翔药业股份有限公司(以下简称"公司")股票交易于 2025 年 7 月 属于股票交易异常波动的情形。 ● 经公司自查并书面问询公司控股股东、实际控制人，截至本公告披露日， 确认不存在应披露而未披露的重大信息。 一、股票交易异常波动的具体情况 公司股票交易于 2025 年 7 月 29 日、7 月 30 日、7 月 31 日连续三个交易日 内收盘价格涨幅偏离值累计超过 20%，根据《上海证券交易所交易规则》的有关 规定，属于股票交易异常波动情形。 二、公司关注并核实的相关情况 针对公司股票异常波动情况，公司对有关事项进行了核查，现将有关情况说 明如下： （一）生产经营情况 经公司自查，公司目前生产经营情况正常，不存在应披露而未披露的重大信 息。 （二）重大事项情况 经公司自查，并向控股股东、实际控制人书面问询确认，截至本公告披露日， 不存 ...

证券日报网讯7月31日晚间，奥翔药业（603229）发布公告称，2025年7月，公司未实施股份回购。 ...

（编辑 任世碧） 证券日报网讯 7月31日晚间，奥翔药业发布公告称，公司股票交易于2025年7月29日、7月30日、7月31 日连续三个交易日内收盘价格涨幅偏离值累计超过20%，属于股票交易异常波动的情形。经公司自查并 书面问询公司控股股东、实际控制人，截至本公告披露日，确认不存在应披露而未披露的重大信息。 ...

证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交3.27亿元，其中，买入成交额为2.16亿 元，卖出成交额为1.11亿元，合计净买入1.05亿元。 具体来看，今日上榜的营业部中，沪股通为第二大买入营业部及第二大卖出营业部，买入金额为 5045.15万元，卖出金额为2022.12万元，合计净买入3023.03万元。 资金流向方面，今日该股主力资金净流入2.61亿元，其中，特大单净流入2.44亿元，大单资金净流入 1741.79万元。近5日主力资金净流入2.45亿元。 奥翔药业(603229)今日涨停，全天换手率13.27%，成交额12.53亿元，振幅11.63%。龙虎榜数据显示， 沪股通净买入3023.03万元，营业部席位合计净买入7475.28万元。 上交所公开信息显示，当日该股因日涨幅偏离值达11.22%上榜，沪股通净买入3023.03万元。 融资融券数据显示，该股最新（7月30日）两融余额为3.15亿元，其中，融资余额为3.14亿元，融券余额 为91.26万元。近5日融资余额合计增加4096.09万元，增幅为14.98%。融券余额合计增加41.90万元，增 幅84.88%。 卖五 财通证券股份有限 ...

Summary of Key Points - The company Aoxiang Pharmaceutical (603229.SH) announced that as of July 31, 2025, it has repurchased a total of 1.9994 million shares through centralized bidding, which represents 0.24% of the company's total share capital [1] - The highest price at which the shares were repurchased was 8.57 CNY per share, while the lowest price was 7.52 CNY per share [1] - The total amount paid for the repurchased shares, excluding transaction fees, was 15.5358 million CNY [1]

Group 1 - The company, Aoxiang Pharmaceutical, announced on July 31 that it has repurchased approximately 2 million shares through centralized bidding, accounting for 0.24% of its total share capital, with a total expenditure of about 15.54 million yuan [2] - The highest price for the repurchased shares was 8.57 yuan per share, while the lowest price was 7.52 yuan per share [2] - For the fiscal year 2024, the company's revenue composition is as follows: raw materials and intermediates account for 95.25%, while technical service fees account for 4.75% [2]

证券代码：603229 证券简称：奥翔药业 公告编号：2025-034 浙江奥翔药业股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 浙江奥翔药业股份有限公司(以下简称"公司")股票交易于 2025 年 7 月 29 日、7 月 30 日、7 月 31 日连续三个交易日内收盘价格涨幅偏离值累计超过 20%， 属于股票交易异常波动的情形。 ● 经公司自查并书面问询公司控股股东、实际控制人，截至本公告披露日， 确认不存在应披露而未披露的重大信息。 （一）生产经营情况 经公司自查，公司目前生产经营情况正常，不存在应披露而未披露的重大信 息。 （二）重大事项情况 经公司自查，并向控股股东、实际控制人书面问询确认，截至本公告披露日， 不存在影响公司股票交易异常波动的重大事项，不存在其他应披露而未披露的重 大事项，包括但不限于重大资产重组、股份发行、收购、债务重组、业务重组、 资产剥离和资产注入等重大事项。 （三）媒体报道、市场传闻、热点概念情况 公司未发现对公司股票交易价格可能产生较 ...

证券代码：603229 证券简称：奥翔药业 公告编号：2025-033 格上限由不超过人民币 14 元/股（含）调整为不超过人民币 13.90 元/股（含）。 具体内容详见公司于 2025 年 7 月 10 日披露的《奥翔药业关于 2024 年度权益分派 实施后调整回购价格上限的公告》（公告编号：2025-032）。 二、回购股份的进展情况 浙江奥翔药业股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/1/27 | | --- | --- | | 回购方案实施期限 | 2025/1/24~2026/1/23 | | 预计回购金额 | 5,000万元~10,000万元 | | 回购用途 | □减少注册资本 √用于股权激励和/或员工持股计划 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 1,999,400股 | | 累计已回购股数占总股本比例 | 0.24% | | ...